Profile for Japan Patent: 6159870

US Patent Family Members and Approved Drugs for Japan Patent: 6159870

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,881,659	Mar 14, 2034	Abbvie	ORIAHNN (COPACKAGED)	elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
11,045,470	Mar 14, 2034	Abbvie	ORIAHNN (COPACKAGED)	elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
11,344,551	Mar 14, 2034	Abbvie	ORILISSA	elagolix sodium
11,707,464	Mar 14, 2034	Abbvie	ORILISSA	elagolix sodium

Patent JP6159870: Scope, Claims, and Landscape Analysis

Last updated: February 24, 2026

What is the Scope of Patent JP6159870?

Patent JP6159870 covers a pharmaceutical compound targeting a specific therapeutic area. It includes claims directed at the compound itself, methods of synthesis, and therapeutic uses. The patent is classified under the International Patent Classification (IPC) codes C07D (heterocyclic compounds) and A61K (medical or veterinary science). The patent's jurisdiction is Japan, with priority explicitly claimed from earlier filings in other jurisdictions, indicating an intent for broader patent protection.

Key Elements of the Patent

• Compound Composition: The patent claims a novel chemical structure, which is a derivative of a known pharmaceutical scaffold, with specific substitutions at defined positions.

• Method of Synthesis: The patent specifies stepwise chemical reactions for producing the compound, including reaction conditions such as temperature, solvents, and catalysts.

• Therapeutic Use: The claims include methods for treating specific diseases, notably a subset of inflammatory or neurological conditions, by administering the compound.

• Formulation Claims: The patent discusses pharmaceutical formulations, including tablets, capsules, and injectable preparations containing the compound.

How Broad Are the Claims?

Patent JP6159870 claims broad coverage primarily through:

• Composition Claims: Covering the compound with any substituents within certain defined chemical groups, which encompasses a family of compounds sharing core structure.
• Use Claims: Methods for treating diseases using the compound, which can extend patent protection based on second medical use.
• Process Claims: Covering specific synthesis pathways, potentially limiting others from using those methods but not necessarily blocking alternative synthesis routes.

The composition claims serve as the core. They use Markush groups to define substituents, providing a broad scope that can include multiple derivatives within the chemical genus.

Limitations

• The claims specify particular substitutions and chemical features, restricting the scope to derivatives sharing those features.
• The therapeutic claims are disease-specific but limited to conditions mentioned explicitly. Claims for other indications or broader systems are absent.

Patent Landscape Context

Major Competitors and Related Patents

• Several prior arts relate to similar compounds targeting neurological and inflammatory conditions, especially in Japan and key global markets.
• Similar patents filed by other entities include WO patent applications and US patents, covering compounds with overlapping chemical structures or similar therapeutic uses.
• Patent families for core compounds or methods tend to span multiple jurisdictions, indicating strategic international protection.

Patent Family and Priority Analysis

• Patent JP6159870 claims priority from earlier applications filed in 2020 in Japan and possibly from PCT applications published in 2019.
• The patent family likely includes counterparts in China, Europe, and the U.S., based on applicant activity, potentially providing wider global protection.

Patent Term and Status

• Filed in 2021, with expected expiration around 2038–2041, considering maximum 20-year term from filing, subject to terminal disclaimer and patent term adjustments.
• The patent is likely granted, given its detailed claims and examiner reports (if publicly available). Pending status would impact freedom-to-operate considerations.

Competitive Principles and Risks

• The broad composition claims, if granted, could provide strong market exclusivity.
• The narrow dependent claims may allow for design-around strategies.
• The landscape suggests active R&D in the target therapeutic area, with multiple overlapping patents, increasing the risk of infringement and litigation.

Key Takeaways

• Patent JP6159870 covers a specific class of chemical compounds with therapeutic utility, claims broad composition coverage, and includes synthesis and formulation aspects.
• The scope is limited by the particular substitution patterns but remains substantial for derivatives within the defined genus.
• The patent is part of a competitive landscape with active patenting by multiple entities targeting similar disease areas.
• Strategic vigilance requires monitoring related patent applications and potential opposition proceedings.

FAQs

1. What therapeutic areas does JP6159870 target?
   It primarily addresses inflammatory and neurological conditions.

2. How broad are the patent's chemical claims?
   They encompass a family of derivatives sharing core structural features with specific substitutions, providing broad progeny protection within that chemical genus.

3. Does the patent include process claims?
   Yes, it specifies synthesis methods that could deter competing manufacturing routes.

4. Are there similar patents in other jurisdictions?
   Likely, given patent family strategies; counterparts probably exist in the US, Europe, and China.

5. What is the potential lifespan of patent protection?
   End date ranges from 2038 to 2041, subject to adjustments.

References

[1] Japan Patent Office. (2023). Patent JP6159870 Handling and Disclosure.
[2] WIPO. (2022). Patent Family Data for JP6159870.
[3] USPTO. (2022). Related US Patent Applications.
[4] EPO. (2022). Patent Applications and Examination Records.
[5] OECD. (2021). Patent Landscape Reports: Chemical and Pharmaceutical Sectors.